Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin for Chemotherapy-induced Neuropathic Pain
NCT02989129Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label trial of quercetin in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Change in Neuropathic Pain Intensity at 12 weeks. Planned start Apr 2018; status: withdrawn.
02
Drugs
quercetin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT02989129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989129.